S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001)
Solid Tumors

About this trial
This is an interventional treatment trial for Solid Tumors focused on measuring C-C motif chemokine receptor 8 (CCR8)
Eligibility Criteria
Inclusion Criteria:
- Male or female participant must be at least 18 years of age inclusive (or complies with country-specific regulatory requirements, at least 20 years of age in Japan), at the time of signing the informed consent.
- Participants with histologically or cytologically confirmed advanced (locoregionally recurrent, not amenable to curative therapy) or metastatic solid tumors who have no standard therapies with a proven clinical benefit, or who are intolerant to or unwilling to receive these therapies for any reasons.
- Measurable disease by RECIST 1.1.
- (Part A only) Participants should have 1 of the following tumor types: malignant melanoma (MEL), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), or triple-negative breast cancer (TNBC), esophageal cancer (EC; esophageal squamous cell carcinoma and adenocarcinoma), or gastric cancer (GC; gastric and gastroesophageal junction adenocarcinoma).
- (Part B only) Participants should have 1 of specific histologically or cytologically confirmed tumor types selected by the sponsor after completion of Part A-1.
- (Part C only) Participants should have 1 of specific histologically or cytologically confirmed tumor types selected by the sponsor after completion of Part A-2.
- Participants should be willing and able to provide permission to access archival formalin-fixed paraffin-embedded (FFPE) tumor tissues (as block or unstained slides) for this study.
- Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples.
- (At selected sites only) Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples. Fresh tissue samples are required as these will be used for the proof of mechanism analysis.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
- An estimated life expectancy of at least 12 weeks.
- Adequate hematologic and organ function as confirmed by laboratory values.
- QT interval corrected with the Fridericia formula (QTcF) ≤ 480 milliseconds in 12-lead electrocardiogram (ECG) at Screening.
Exclusion Criteria:
- Presence or history of autoimmune diseases or immune-mediated diseases that require chronic use of systemic corticosteroids (> 10 mg of prednisone equivalent per day), immunosuppressive agents, or disease-modifying agents.
- Active clinically significant bacterial, viral or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral antiinfectives within 4 weeks before the first dose of study intervention.
- Uncontrolled or clinically significant cardiovascular disease defined as New York Heart Association (NYHA) classification III or IV.
- A positive test for hepatitis B surface antigen (HBsAg) and/or hepatitis C virus (HCV) antibody (a confirmatory HCV RNA test if HCV antibody was positive).
- A positive serological test for human immunodeficiency virus (HIV) infection.
- Known history of any other relevant congenital or acquired immunodeficiency.
- Known history of severe allergy, hypersensitivity, anaphylaxis, or any serious adverse reaction to any component of study intervention or formulation components and/or any other monoclonal antibodies.
- Women who are pregnant or breastfeeding or trying to become pregnant.
- Clinical evidence of uncontrolled brain metastasis.
- Clinical evidence of any active second invasive malignancy (except stable prostate cancer on watchful waiting).
- (Parts A-2 and C only): Participants who developed an immune-related adverse event (irAE) during prior pembrolizumab treatment that required a delay in the scheduled administration for more than 4 weeks due to any grade of irAEs or led to permanent discontinuation of pembrolizumab. Also, participants whose previous irAE due to pembrolizumab has not resolved to ≤ Grade 1 and/or still requires corticosteroids (> 10 mg of prednisone-equivalent per day).
- Prior treatment with systemic anticancer drugs (including any investigational medicinal products) within 28 days or 5 half-lives (whichever is shorter) before the first dose of study intervention.
- Prior major surgery within 28 days before the first dose of study intervention.
- Prior extended field radiotherapy within 28 days before the first dose of study intervention (within 14 days for limited field radiation for palliation).
- Participants who have not recovered from any previous treatment toxicities to ≤ Grade 1 or baseline (except alopecia and peripheral neuropathy) before the first dose of study intervention.
- Prior treatment with anti-CCR8 antibody for any indication.
- Receipt of a live, attenuated vaccine within 28 days before the first dose of study intervention.
Sites / Locations
- Angeles Clinic and Research CenterRecruiting
- Henry Ford Health CenterRecruiting
- Fox Chase Cancer CenterRecruiting
- National Cancer Center Hospital EastRecruiting
- Osaka University HospitalRecruiting
- National Cancer Center HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Part A-1: S-531011 Monotherapy
Part A-2: S-531011 + Pembrolizumab
Part B: S-531011 Monotherapy
Part C: S-531011 + Pembrolizumab
Participants will receive escalating doses of S-531011 by intravenous infusion for up to approximately 12 months.
Participants will receive escalating doses of S-531011 in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
Participants will receive S-531011 at the the RP2D by intravenous infusion for up to approximately 12 months.
Participants will receive S-531011 at the RP2D in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.